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X-­‐linked	  adrenoleukodistrophy	  (X-­‐ALD)	  is	  the	  most	  common	  peroxisomal	  disorder.	  The	  disease	  is	  caused	  by	  muta>ons	  in	  the	  ABCD1	  gene	  that	  encodes	  the	  
peroxisomal	  membrane	  protein	  ALDP	  which	  is	  involved	  in	  the	  transmembrane	  transport	  of	  very	  long-­‐chain	  faGy	  acids	  (VLCFA;	  >22).	  A	  defect	  in	  ALDP	  results	  
in	  elevated	   levels	  of	  VLCFA	   in	  plasma	  and	  >ssues.	  The	  clinical	   spectrum	   in	  males	  with	  X-­‐ALD	   ranges	   from	   isolated	  adrenocor>cal	   insuﬃciency	  and	   slowly	  
progressive	  myelopathy	   to	  devasta>ng	  cerebral	  demyelina>on.	  The	  majority	  of	  heterozygous	   females	  will	  develop	  symptoms	  by	   the	  age	  of	  60	  years.	  We	  
describe	  a	   family	  with	   six	  members	   carrying	  a	  novel	  heterozygous	  muta>on	   IVS4+2T>A	   (c.1393+2T>A)	  of	   the	  ABCD1	  gene	  highligh>ng	   the	  wide	   range	  of	  
phenotypic	  manifesta>ons	  of	  ALD.	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Pa#ent	   V:2.	   In	   2015,	   this	   9-­‐year-­‐old	   child	   referred	   to	   the	   pediatric	  
endocrine	   clinic	   for	   obesity	   and	   raised	   TSH,	   his	   neurological	  
examina>on	  was	  normal.	  Brain	  MRI	  revealed	  an	  unequivocal	  paGern	  of	  
ALD.	   The	   1	   ug-­‐synacthen	   test	   detected	   primary	   adrenal	   insuﬃciency.	  
The	   fas>ng	   plasma	   levels	   of	   VLCFA	  were:	   C26:0	   1.41	   umol/L	   (normal	  
0.25-­‐0.65).	   His	   C24:0/C22:0	   and	   C26:0/C22:0	   were	   0.99	   (normal	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Pa#ent	   IV:3.	   In	   2007,	   this	   43-­‐year-­‐old	   pa>ent	   developed	   progressive	   gait	  
disturbance	   due	   to	   weakness	   of	   the	   extremi>es	   and	   dysarthria.	   Neurological	  
examina>ons	   revealed	   a	   spas>c	   parapare>c	   gait,	   	   bilaterally	   hyperreﬂexia	   of	  
knee,	  ankle	  jerks,	  Hoﬀman	  and	  Babinki	  signs.	  Over	  the	  years,	  several	  brain	  and	  
cervico-­‐dorsal	   magne>c	   resonance	   were	   normal.	   In	   2015	   brain	   MRI	   become	  
posi>ve	   for	   ALD.	   Cerebrospinal	   ﬂuid	   studies	  were	   also	   performed	   and	   it	   was	  
within	  normal	   limits.	   The	   laboratory	   tests	   revealed	  normal	   serum	  cor>sol	  but	  
elevated	   adrenocor>cotropic	   hormone,	   426.2	   pg/mL	   (normal	   7.2-­‐63.3).	   The	   1	  
ug-­‐synacthen	  test	  showed	  a	  peak	  cor>sol	  response,	  conﬁrming	  primary	  par>al	  
adrenal	   insuﬃciency.	   The	   fas>ng	   plasma	   levels	   of	   VLCFA,	  measured	  with	   gas	  
chromatography-­‐mass	   spectrometry,	   were:	   C22:0,	   23.77	   umol/L	   (normal	  
17.00-­‐72.00),	  C24:0,	  47.66	  umol/L	  (normal	  12.00-­‐62.00);	  and	  C26:0	  2.13	  umol/L	  
(normal	   0.25-­‐0.65).	   His	   C24:0/C22:0	   and	   C26:0/C22:0	   were	   signiﬁcantly	  
elevated	  at	  2.01	  (normal	  0.50-­‐1.10)	  and	  0.09	  (normal	  0.01-­‐0.03),	  respec>vely.	  	  
Methods	  
We	  obtained	  two	  products	  in	  the	  aﬀected	  male	  (TM)	  and	  his	  family	  (PE)	  (Fig.	  3):	  
a	   low	  molecular	  weight	   product	   (es>mated	   length	   c.a.	   240	   bp),	  which	   is	   also	  
present	  in	  the	  normal	  control	  (SM),	  and	  a	  band	  of	  approximately	  280	  bp	  which	  
was	  only	  present	  in	  the	  proband	  (TM)	  and	  his	  family	  (PE).	  The	  280	  bp	  fragment	  
was	   cloned	   and	   sequenced	   and	   we	   iden>ﬁed	   a	   dele>on	   of	   121	   bp	  
encompassing	  part	  of	  exon	  4	  and	  the	  ﬁrst	  two	  nucleo>des	  of	  exon	  5	  (Fig.	  4).	  The	  
aberrant	   splicing	   results	   in	   a	   frame-­‐shii	   in	   the	   coding	   sequence	   leading	   to	   a	  
premature	  stop	  codon.	  This	  dele>on	  should	   lead	   to	   the	  synthesis	  of	  a	   shorter	  
protein	   (from	   745	   to	   516	   aa)	   lacking	   most	   of	   the	   ABC	   transporter	   domain	  
(located	  from	  aa	  474	  to	  aa	  700).	  	  
Genomic	   DNA	   was	   extracted	   from	   peripheral	   whole	   blood	   samples	   collected	  
from	  the	  pa>ent	  and	  his	  family.	  All	  samples	  were	  taken	  aier	  informed	  consent	  
was	   obtained.	   The	   splice	   junc>ons	   and	   all	   coding	   regions	   of	   the	  ABCD1	   gene	  
were	   ampliﬁed	   by	   polymerase	   chain	   reac>on	   using	   speciﬁc	   primers.	   The	   PCR	  
products	   were	   directly	   sequenced	   using	   capillary	   electrophoresis	   sequencing	  




Fig.	  3.	  	  RT-­‐PCR.	  	  
Fig.	  4.	  Sequence	  analysis	  of	  cloned	  RT-­‐PCR	  of	  the	  aﬀected	  male.	  Sequence	  chromatogram	  
showing	  a	  par>al	  dele>on	  of	  exon	  4	  and	  5.	  The	  sequence	  corresponding	  to	  the	  normal	  
splicing	  event	  	  is	  reported	  in	  the	  upper	  part	  of	  the	  ﬁgure.	  The	  underline	  italic	  sequence	  is	  
absent	  in	  the	  pa>ent’s	  mature	  transcript.	  
A	   B	   C	  
A1	   B1	   C1	  
Fig.	  1	  The	  cross	  inheritance	  of	  recessive	  X-­‐linked	  adrenoleukodistrophy	  
alleles	  in	  consanguineous	  pedigree	  
Fig.2	  Pa>ent	  IV:3.	  Brain	  and	  cervico-­‐dorsal	  MRI	  (A,	  B,	  C).	  Pa>ent	  V:2.	  Brain	  MRI	  shows	  the	  
typical	  paSern	  of	  ALD	  (A1,	  B1,	  C1).	  
Discussion
This	   is	   the	  ﬁrst	  published	  report	  of	   the	   IVS4+2	  T>A	  muta>on	   in	   intron	  4	  of	   the	  ABCD1	  gene.	  Although	  there	  had	  been	  no	  systema>c	  study	  conducted	  to	  
support	   the	  predicted	  structure	  and	   func>on	  of	  ALDP,	  previous	  study	  showed	  that	  missense	  muta>ons	   in	  ABCD1	   leading	   to	  decrease	   in	  ALDP	   levels	  may	  
interfere	  with	  the	  peroxisomal	  targe>ng	  mechanism	  of	  the	  newly	  synthesized	  ALDP	  molecules,	  their	  correct	  membrane	  inser>on	  and	  folding.	  It	  is	  plausible	  
that	  our	  muta>on,	  similar	  to	  other	  trunca>ng	  muta>ons	  in	  ABCD1,	  can	  result	  to	  the	  same	  defects	  of	  peroxisomal	  targe>ng	  as	  reported.	  We	  showed	  that,	  
within	   individual	   kindreds	   with	   the	   same	  muta>on,	   diﬀerent	   phenotypes	   of	   the	   en>re	   clinical	   and	   radiological	   spectrum	   of	   X-­‐ALD	   since	   asymptoma>c	  
pa>ent,	   could	   be	   detected.	   Thus,	   early	   diagnosis	   is	   essen>al,	   since	   in	   some	   cases	   treatment	   is	   available,	   such	   as	   allogenic	   heterogeneous	   hallograi	  
transplanta>on	  in	  the	  early	  stage	  and	  endocrine	  replacement	  therapy	  for	  adenocro>cal	  insuﬃciency.	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